STOK

Stoke TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

Probability

Target price

$46.00

+56.1% vs current

Most likely

Base case

Probability

Target price

$35.00

+18.8% vs current

B-

Bear case

Probability

Target price

$24.00

-18.5% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

T+1 sentiment looks mixed but stable rather than strongly positive. Primary company news flow was constructive on long-term OLE data, EMPEROR progress, and runway, while the financial print itself was only modestly supportive because revenue was soft and losses remained elevated. The stock's May 8, 2026 session was described as muted versus the May 7 anchor close, and no confirmed post-print analyst target resets were available from checked sources; together with the packet's negative deterministic prior, that supports a tentative monitoring stance rather than a momentum call.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Impact

tentative

Confidence

AI events

2026-05-31catalystPost-earnings digestion after mixed Q1 print and business updateMedium impact

Q1 2026 results were mixed: net loss was $50.0 million, revenue was $6.2 million, cash was $411.0 million, and management reiterated runway into 2028 while highlighting durable long-term zorevunersen data and launch-readiness spending. Versus pre-print expectations around a roughly $0.80 loss and about $6.48 million to $7.07 million of revenue from secondary sources, the setup looks like a slight EPS beat with a modest revenue miss, which supports a cautious T+1 monitoring read rather than a standard-conviction thesis change. [#8-K-2026-05-07] [#10-Q-2026-05-07]

2026-06-30eventEMPEROR enrollment completion in June 2026 could de-risk the lead programHigh impact

Management said EMPEROR enrollment of approximately 150 patients is expected to complete in June 2026; as of May 5 about 130 patients had been randomized, with the remaining patients moving through screening. Hitting that milestone would modestly de-risk execution ahead of the pivotal readout, but it does not resolve efficacy risk. [#8-K-2026-05-07]

2027-06-30catalystMid-2027 pivotal readout and planned rolling NDA start remain the real value inflectionHigh impact

Stoke expects mid-2027 data from EMPEROR to support completion of the planned rolling U.S. NDA submission, which management plans to initiate in Q1 2027. This is the main valuation driver because Stoke still has no approved product sales and the equity case remains concentrated in zorevunersen. [#8-K-2026-05-07] [#10-Q-2026-05-07]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology